The second generation small molecule Met inhibitor, PHA665752, has been shown effective in MM, blocking the phosphorylation of Met, Akt, Erk1/2 and p70-S6K, in vitro alone [45] or in combination with rapamycin, revealing that combination targeting of mTOR and Met suppresses Akt pathway activation and more effectively decreases cell growth [66]. The gene discussed is AKT1; the disease is Miyoshi myopathy.